CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
Last update: 10 hours ago39.75
-1.19 (-2.91%)
| Previous Close | 40.94 |
| Open | 41.64 |
| Volume | 901,406 |
| Avg. Volume (3M) | 938,667 |
| Market Cap | 3,206,480,384 |
| Price / Sales | 1.40 |
| Price / Book | 4.80 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 6,371,669 |
| Foresite Capital Management Vi Llc | 30 Sep 2025 | 2,221,474 |
| Kynam Capital Management, Lp | 30 Sep 2025 | 2,005,205 |
| Orbimed Advisors Llc | 30 Sep 2025 | 1,726,850 |
| Rtw Investments, Lp | 30 Sep 2025 | 1,701,216 |
| Avidity Partners Management Lp | 30 Sep 2025 | 1,600,899 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Guggenheim, 126.42%) | Buy |
| Median | 66.00 (66.04%) | |
| Low | 47.00 (JP Morgan, 18.24%) | Buy |
| Average | 68.17 (71.50%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 40.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 11 Dec 2025 | 70.00 (76.10%) | Buy | 41.61 |
| Truist Securities | 24 Nov 2025 | 62.00 (55.97%) | Buy | 43.56 |
| RBC Capital | 17 Nov 2025 | 61.00 (53.46%) | Buy | 41.25 |
| Guggenheim | 08 Oct 2025 | 90.00 (126.42%) | Buy | 40.71 |
| JP Morgan | 26 Sep 2025 | 47.00 (18.24%) | Buy | 37.54 |
| Morgan Stanley | 17 Sep 2025 | 79.00 (98.74%) | Buy | 37.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Dec 2025 | Announcement | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer |
| 26 Nov 2025 | Announcement | CG Oncology Announces New Board Member and Board Transition |
| 25 Nov 2025 | Announcement | CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting |
| 14 Nov 2025 | Announcement | CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |